Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 12, 2020 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate the long-term safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. 

This study concluded that ibrutinib was safe and effective in the long-term in this group.   

Some background

Ibrutinib (Imbruvica) is a type of targeted therapy called a tyrosine kinase inhibitor (TKI) used in treatment of B cell cancers such as chronic lymphocytic leukemia (CLL). It has shown very good results in short-term studies. However, the long-term safety and effectiveness of ibrutinib in patients with CLL or small lymphocytic leukemia (SLL) remain under investigation. 

Methods & findings

This study involved 132 patients with first-time or relapsed/refractory CLL or SLL. All patients were treated with ibrutinib. Patients were followed for an average of 8 years.  

The overall response rate (ORR) was 89%. The ORR for the first-line group was 87% and 89% in the relapsed/refractory group. The complete response (CR) was 35% for the first-line group and 10% in the relapsed/refractory group.  

The estimated 7-year progression-free survival (PFS) rate was 83% in the first-line group and 34% in the relapsed/refractory group. The average PFS was not reached with first-line ibrutinib. In the relapsed/refractory group, the median PFS was 52 months overall.  

The estimated 7-year overall survival (OS) rate was 84% in the first-line group and 55% in relapsed/refractory group. 

28% of patients had hypertension (high blood pressure) as a serious side effect. 24% of patients had serious pneumonia and 18% of patients had serious neutropenia (low-level white blood cells). Side effects leading to ending treatment were only observed in the relapsed/refractory group. 

The bottom line

This study concluded that ibrutinib was safe and effective in the long-term in patients with first-line or relapsed/refractory CLL or SLL.  

The fine print

This study had a small number of participants. The study was funded by Pharmacyclics LLC, the manufacturer of ibrutinib.

Published By :

Clinical Cancer Research

Date :

Mar 24, 2020

Original Title :

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study.

click here to get personalized updates